Respiratory Depression ' Pipeline Review, H2 2012

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Respiratory Depression ' Pipeline Review, H2 2012
Published on September 2012

Report Summary


Summary

Global Markets Direct's, 'Respiratory Depression - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic
pipeline. This report provides information on the therapeutic development for Respiratory Depression, complete with latest updates,
and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for
Respiratory Depression. Respiratory Depression - Pipeline Review, Half Year is built using data and information sourced from Global
Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases
from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated
disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Depression.
- A review of the Respiratory Depression products under development by companies and universities/research institutes based on
information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Depression pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Depression.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive
advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Depression pipeline depth and focus of Indication
therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to
enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Respiratory Depression ' Pipeline Review, H2 2012 (From Slideshare) Page 1/6


Table of Content

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Respiratory Depression Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Respiratory Depression 7
Respiratory Depression Therapeutics under Development by Companies 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Discovery and Pre-Clinical Stage Products 12
Respiratory Depression Therapeutics ' Products under Development by Companies 13
Companies Involved in Respiratory Depression Therapeutics Development 14
Cortex Pharmaceuticals, Inc. 14
Galleon Pharmaceuticals 15
Sihuan Pharmaceutical Holdings Group Ltd. 16
Respiratory Depression ' Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
CX-1796 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
R&D Progress 23
R&D Progress 24
nalmefene - Drug Profile 26
R&D Progress 26
GAL-054 - Drug Profile 27



R&D Progress 27
Respiratory Depression Therapeutics ' Drug Profile Updates 28
Respiratory Depression ' Product Development Milestones 29
Featured News & Press Releases 29
May 07, 2012: Galleon Reports Positive Results From Phase I Study Of GAL-021 For Treatment Of Respiratory Depression 29
Aug 24, 2011: Cortex Receives US Patent For Use Of Ampakine Molecules To Treat Respiratory Depression 29
Nov 04, 2009: Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure In Animal Studies 30
Nov 03, 2008: Cortex's AMPAKINE Research In Opioid Makes Windhover's Top 10 List of Neuroscience Projects Available For
Partnering 30
Oct 29, 2008: Discovery Labs Kl-4 Surfactant Data Presented At Two Key Medical Meetings 31
Oct 06, 2008: Cortex's AMPAKINE Compound, CX717, Achieves Primary Endpoints In Second Phase IIa Respiratory Depression
Study 31
Aug 06, 2008: Cortex's AMPAKINE Molecule CX717 Reports Positive Effects In Opiate'Induced Respiratory Depression In Phase IIa
Clinical Study 32
Jul 31, 2008: Cortex To Provide Top Line Data For CX717 Clinical Trial For The Prevention Of Opiate-Induced Respiratory
Depression In Humans 33
Mar 07, 2008: Cortex Receives Approval From German Regulatory Authority To Proceed With Two Clinical Trials For AMPAKINE
CX717 For The Acute Treatment Of Respiratory Depression 33
Feb 15, 2007: Health Canada Approves Significant New Medical Claims for COLD-fX 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables

Number of Products Under Development for Respiratory Depression, H2 2012 7
Products under Development for Respiratory Depression ' Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Cortex Pharmaceuticals, Inc., H2 2012 14
Galleon Pharmaceuticals, H2 2012 15
Sihuan Pharmaceutical Holdings Group Ltd., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Respiratory Depression Therapeutics ' Drug Profile Updates 28

List of Figures



Number of Products under Development for Respiratory Depression, H2 2012 7
Products under Development for Respiratory Depression ' Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Discovery and Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Respiratory Depression ' Pipeline Review, H2 2012

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

Respiratory Depression ' Pipeline Review, H2 2012